1461087691-1efe54ec-6dfd-41a7-990b-19b9a426eacf

1. A method for multiplexing control signals, the method comprising:
coding control signals for at least one user signals to correspond to a structure of a transmission block for the control signals among one or more dedicated resource block;
multiplexing the control signals for the at least one user signals in the dedicated resource block; and
transmitting the control signals,
wherein the dedicated resource block is allocated for transmitting the control signals separately from data signals among a plurality of transmission resource blocks.
2. The method of claim 1, wherein the control signals are multiplexed by using different subcarriers of the dedicated resource block to each of the control signals.
3. The method of claim 1, wherein the control signals are multiplexed by multiplying by different sequences to each of the control signals.
4. The method of claim 1, wherein pilot signals are multiplexed in the dedicated resource block.
5. The method of claim 4, wherein a structure of the transmission block for the control signals is the same as that of a transmission block for the pilot signals.
6. The method of claim 5, the pilot signals are multiplexed in a same manner with corresponding control signals.
7. The method of claim 4, wherein a structure of the transmission block for the control signals is different from that of a transmission block for the pilot signals.
8. The method of claim 7, the pilot signals are multiplexed in a different manner with corresponding control signals.
9. The method of claim 7, wherein the pilot signals are allocated to different transmission blocks for the pilot signals to each of corresponding control signals.
10. The method of claim 7, wherein the pilot signals is a sequence having orthogonality.
11. The method of claim 10, wherein the sequence is a CAZAC (Constant Amplitude Zero AutoCorrelation) sequence.
12. The method of claim 7, wherein the pilot signals is coded by using code having orthogonality.
13. The method of claim 12, wherein the code having orthogonality is at least one of hadamard code and simplex code.
14. The method of claim 3, wherein the sequences are generated through at least one of a method for constituting sequences differently and a method for performing cyclic shift to the sequence.
15. The method of claim 14, wherein the sequences constituted differently are allocated to each cell, and sequences generated by performing cyclic shift to the sequence are allocated to each user of the each cell.
16. The method of claim 14, wherein the sequences allocated to neighboring cells are cyclic shifted with different pattern.
17. The method of claim 3, wherein the sequences are multiplied by the control signals in at least one direction of a time axis and a frequency axis of the dedicated resource block.
18. The method of claim 3, wherein a length of the sequences is determined by the number of subcarriers of the dedicated resource block if the sequences are multiplied by the control signals on a frequency axis.
19. The method of claim 1, wherein the control signals are identified for each user.
20. The method of claim 1, wherein the control signals include at least one of channel quality information (CQI), ACKNACK signals, rank indicator (RI), and precoding matrix indicator (PMI).

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A coordination complex, comprising:
a first biologically active moiety;
a second biologically active moiety; and
a metal,
wherein the first biologically active moiety and second biologically active moiety are each bound to the metal by at least one binding site,
wherein the first biologically active moiety and second biologically active moiety are different; and
wherein the first biologically active moiety and the second biologically active moiety both have a biological effect on a target tissue.
2. The coordination complex of claim 1, wherein both the first biologically active moiety and the second biologically active moiety have a biological effect on a same target tissue.
3. The coordination complex of claim 1, wherein the first biologically active moiety and the second biologically active moiety have a biological effect on a tissue associated with the same disease state.
4. The coordination complex of claim 1, wherein the first biologically active moiety and the second biologically active moiety have a biological effect on a same target tissue associated with a disease state.
5. The coordination complex of claim 3, wherein both the first biologically active moiety and the second biologically active moiety have a biological effect on receptors on the tissue associated with the same disease state.
6. The coordination complex of claim 4, wherein both the first biologically active moiety and the second biologically active moiety have a biological effect on receptors on the same tissue associated with a same disease state.
7. The coordination complex of claim 1, wherein the first biologically active moiety and the second biologically active moiety have more than one binding site that is capable of binding the metal.
8. The coordination complex of claim 1, wherein the binding site comprises a donor atom.
9. The coordination complex of claim 1, wherein the first biologically active moiety, second biologically active moiety, and the metal form a polynuclear complex.
10. The coordination complex of claim 1, wherein the metal is a transition metal.
11. The coordination complex of claim 1, wherein the metal is a s-block metal.
12. The coordination complex of claim 1, wherein the metal is a p-block metal.
13. The coordination complex of claim 1, wherein the metal is a d-block metal.
14. The coordination complex of claim 1, wherein the metal is an inner transition metal of the lanthanide and actinide series.
15. The coordination complex of claim 1, wherein the metal is selected from the group consisting of magnesium, calcium, iron, cobalt, nickel, copper, zinc, palladium, platinum, ruthenium, rhodium, aluminum, cadmium, vanadium, chromium, strontium, and tin.
16. The coordination complex of claim 1, wherein the first biologically active moiety and the second biologically active moiety are capable of potentiating each other.
17. The coordination complex of claim 1, further comprising a component selected from the group consisting of an amino acid, a lipid, a carbohydrate, a nucleic acid, and a peptide.
18. The coordination complex of claim 1, wherein the metal has a biological effect on a target tissue.
19. The coordination complex of claim 1, wherein the metal potentiates the biological effect of at least one of the first biological moiety and the second biological moiety.
20. A method for enhancing the biological effect of biologically active moieties, comprising:
forming a coordination complex comprising a first biologically active moiety, a second biologically active moiety, and a metal,
wherein the first biologically active moiety and the second biologically active moiety are each bound to the metal by at least one binding site,
wherein the first biologically active moiety and the second biologically active moiety are different, and
wherein the first biologically active moiety and the second biologically active moiety both have a biological effect on a target tissue.
21. The method of claim 20, wherein the forming of the coordination complex enhances the pharmacodynamic properties through synergistic pharmacokinetic application of the first biologically active moiety and the second biologically active moiety.
22. A method of treatment, comprising:
administering a coordination complex comprising at least a first biologically active moiety, a second biologically active moiety, and a metal,
wherein the first biologically active moiety and the second biologically active moiety both have a biological effect on a target tissue.
23. The coordination complex of claim 22, wherein both the first biologically active moiety and the second biologically active moiety have a biological effect on a same target tissue.
24. The coordination complex of claim 22, wherein the first biologically active moiety and the second biologically active moiety have a biological effect on a tissue associated with the same disease state.
25. The coordination complex of claim 22, wherein the first biologically active moiety and the second biologically active moiety have a biological effect on a same target tissue associated with a disease state.
26. The coordination complex of claim 24, wherein both the first biologically active moiety and the second biologically active moiety have a biological effect on receptors on the tissue associated with the same disease state.
27. The coordination complex of claim 25, wherein both the first biologically active moiety and the second biologically active moiety have a biological effect on receptors on the same tissue associated with a same disease state.
28. The method of claim 22, wherein at least the first biologically active moiety potentiates the biological effect of the second biologically active moiety.